Asia
DND Pharmatech Wins KRW1.83 Billion Anti-Obesity Drug Formulation Contract from Pfizer; Shares Rise 3%
DND Pharmatech (KOSDAQ:347850) secured a contract to provide research services for the formulation development of an anti-obesity drug from New York-based biomedical firm Pfizer, according to a Thursday filing with the Korea Exchange.The deal, valued at 1.83 billion won, is valid till Nov. 30.Shares of DND Pharmatech rose nearly 3% in recent trade.
KOSDAQ:347850
